Cellectar Biosciences Inc (NASDAQ: CLRB) is likely to have an overwhelmingly strong day in the market today after the company announced the design of the fifth cohort of its Phase 1 trial surrounding CLR 131. Here’s what we saw from the announcement:
CLRB Announces Design Of Cohort 5
As mentioned above, Cellectar Biosciences is likely to have a strong day in the market today after the compay announced the design of the multiple dose fifth cohort of its Phase 1 dose escalation safety trial of CLR 131 as a treatment for relapsed or refractory multiple myeloma. During the fifth cohort, CLRB will administer two 15.625 mCI/m2 doses which will be given one week apart. This leads to the same total dose provided to patients that resulted in a partial response in Cohort 4.
Patients that take part in the fifth cohort will receive a total of 2 doses of CLR 131 as 30 minute infusions on their first seven days. From there, these patients will be evaluated over the course of 85 days to determine the safety and efficacy of the treatment in line with the study protocol. In a statement, Natalie Callander, M.D., professor of medicine, director at the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, and lead investigator for the CLRB Study, had the following to offer:
“Given the encouraging results we’ve observed to date in previous cohorts, we hope to see similar, or perhaps even improved safety results in this arm of the trial… Previous participants have asked us if it was possible to receive additional doses, as the therapy has been so well tolerated.”
The above statement was followed up by Jim Caruso, president and CEO at CLRB. Here’s what he had to say:
“This fifth cohort represents an important opportunity to better understand the clinical utility of a split dose regimen and to further explore the safety and efficacy of CLR 131. Utilizing two doses provides an opportunity to increase the total amount of drug delivered to the patients which could result in improved efficacy while maintaining similar or better safety profile… Clinical assessment, along with the improved benefits demonstrated by two doses in preclinical studies, suggest to us that the protocol changes should enhance our chances to see improved patient outcomes in this and future study arms.”
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on CLRB. In particular, we’re interested in continuing to follow the story surrounding CLR 131 as the treatment has proven to be a promising treatment in previous cohorts. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!